| Financial
Times Deutschland Since its launch on February 21st 2000 Financial
Times Deutschland stands for modern, intelligent business and financial
journalism. Its journalistic motto is: choice and opinion. FTD reports
critically and comprehensively, quickly getting to the very heart
of complex issues. It covers topics from the Old Economy as well
as E-Business and growth industries. "One brand, all forms
of media" - FTD thinks and acts in a networked manner. Thus
the news in the print edition is augmented by its internet service,
SMS and WAP services, Palm downloads or information for the Rocket
eBook as well as the FTD audio service. This means up-to-date coverage,
even after the copy deadline. It means business news anytime, anywhere.
|
 |
| BioSpace,
Inc. is a specialized provider of web-based products and information
services to the life sciences. The company’s premier Website,
www.biospace.com
is the Internet’s most comprehensive life sciences-related
information and service resource, attracting 800,000 unique visitors
and over 4 million page views monthly. Recognizing the tidal wave
of information being published in the life sciences, BioSpace has
developed products and services that more efficiently deliver information
in a context that is relevant to the end user. Offered both on the
Internet, or an enterprise Intranet, BioSpace’s suite of Enterprise
Portal Services includes an information management tool called BioSpace
LInKS™ Solution, and CCIS, a Clinical Competitive Intelligence
System. Additionally the company leverages its extensive online
community to offer highly popular life sciences industry Career
Fairs. San Francisco-based BioSpace.com was launched in 1995. |
 |
| Biotechnology Investment Today Biotechnology Investment Today is a quarterly review journal for stakeholders in the biotechnology industry. The magazine covers therapeutic and technology sectors within the industry as well as critical operational and financing issues that directly affect company and shareholder value. Topics covered in recent issues include: Cancer Therapeutics, Pharmacogenomics, M&A, Capital Markets and Pathways to Market. The magazine also covers emerging markets and in 2002 will review Australia, Israel, Singapore and Japan. Biotechnology Investment Today is supported by a global seminar and investor network series with events held regularly in the US and Europe. |
 |
| BioWorld Today BioWorld Today, the newspaper of record for the biotechnology industry, is read by thousands of biotechnology professionals worldwide for its hard-hitting, objective news reporting. BioWorld Today is delivered by fax and e-mail every business morning, and is also found exclusively online at www.BioWorld.com. The BioWorld Online web site has been internationally recognized as the most comprehensive resource for strategic biotechnology news and information available today. In addition to original daily news reporting, BioWorld offers an extensive searchable database with more than 11 years of biotechnology archives. This site is not only a great source for insightful, up-to-the-minute news coverage, but a veritable library of information on the developments of the industry as well. With a quick search, BioWorld subscribers have instant access to a wealth of biotechnology market intelligence from every biotech hotspot around the globe. BioWorld does not post press releases, but rather uses information that is researched and written by the top business and science reporters in the industry. With nearly 20 writers spread throughout eight countries, BioWorld covers news on public companies and hard-to-find information on private companies. Our seasoned reporters get the inside scoop on what’s happening within the corporate walls, on regulatory issues in Washington and elsewhere, and on scientific breakthroughs worldwide. This news coverage of the biotechnology industry is 100% original and only available at BioWorld! BioWorld Products:
|
 |
| BioVenture View is the definitive twice-monthly newsletter for the global biotechnology industry and has been providing senior executives with the information they need to stay ahead of the competition. Each monthly issue provides an informative and incisive package of analysis and data, including:
|
 |
| Finance Finance is a monthly from two of the leading German publishing houses, Frankfurter Allgemeine Zeitung and manager magazin. FINANCE is the first authoritative publication on all aspects of the corporate finance market in Germany. Editorial topics are mergers and acquisitions, venture capital, going public, buy-outs and private equity. FINANCE particularly emphasizes the German medium-sized and start-up company sector. The guaranteed circulation is 25,000 copies a month. The price for annual subscription is DEM 126,-. For subscription please call +49 40 3007 25 34, or fax +49 40 3007 3070. |
 |
| Genomika Available electronically and in print, Genomika is an up-to-the-minute newsletter providing an informative and incisive package of news and analysis on the fast-expanding field of drug discovery technologies. Published 22 times a year Genomika encompasses genomics, proteomics, bioinformatics, SNP analysis and more. Coverage includes:
Genomika is available electronically in a number of formats including PDF. For your free sample copy visit www.genomika.com or email genomika@pjbpubs.com |
 |
| GoingPublic Media AG Founded in 1998 GoingPublic Media AG is today one of the leading companies in Germany publishing magazines on venture capital and corporate finance contents as well as small and mid cap research. In addition to the monthly released GoingPublic Magazin and its well known yearly special editions like “IPO- and Venture Capital Guide Germany”, “Biotechnology “or “Investor Relations” which are largely meant as reference books, the company publishes the likewise monthly VentureCapital Magazin. Founded in 2000 as a supplement for the GoingPublic subscribers, VentureCapital Magazin started into a new era as an independent magazin in July 2002 and focuses on private equity, buy-outs and M&A. The brand is a synonym for growth, innovation, entrepreneurial culture and equity financing. Special topics are additionally treated in supplements and special editions. On October 31 the first special edition on “Nanotechnology” will be released. It examines requirements and realities of this promising industry. Furthermore, GoingPublic Media operates the online-service GoingPublic Online (www.goingpublic.de) and the corporate publishing division (GoingPublic Services) publishes about 20 magazines and newsletters for well-known venture capital companies and financial institutions a year. Orders and subscriptions For more information, please contact us at 0049-8171-419650,
|
 |
| Nature
Biotechnology For over 130 years, the Nature Publishing Group
has delivered high-quality, fairly priced information to the global
science market. Nature continually provides over 660,000 readers
with the most up-to-date scientific developments and independent
editorial comment from around the world. And our research journals
offer exciting and high-impact research and the latest scientific
News & Views within their respective disciplines. Keeping up with the deluge of scientific research
is a constant challenge for those in science and business whose
time is valuable and limited. Nature Biotechnology aims to cut through
the noise and present only the hard data, essential news, and expert
analysis of biotechnology research in scientific and commercial
development. Providing a one-stop digest of the research that is
transforming biology and generating the future products for healthcare,
agriculture, and the environment. Over 17 years of experience ensures
that Nature Biotechnology will provide you with the essential research
for the business of biotechnology. |
 |
| Pharmaprojects Pharmaprojects is the leading source of business-critical intelligence on drugs in global R&D providing users with a comprehensive and accurate view of drug development. Pharmaprojects tracks every significant new drug under development. It contains analysis on over 28000 drug candidates investigated since 1980 and detailed profiles on over 1300 companies and 217 therapeutic areas - enabling users to track the R&D activities of competitor companies, assess potential business partners, identify licensing opportunities, analyse industry trends and formulate R&D strategy. Committed to providing up-to-date intelligence, our editorial team of 20 scientists gather and research worldwide R&D information from sources including international scientific journals; conferences; stock brokerage & annual reports; company websites; press releases; online news agencies, and continuous two-way communication with our company contacts. For more information, call us on +44 (0)20 8332-8820 or email us at pharmaprojects.enquiry@pjbpubs.com or visit our website. |
 |
| Scrip Reports Scrip Reports, a division of PJB Publications Limited, provide the highest standard of focused business intelligence in the pharmaceutical industry. With over 30 new titles per year, the reports cover strategic management issues, enabling technologies, therapeutics, drug discovery, biotechnology, regulatory affairs and e-commerce. An exciting new title from Scrip Reports' Biotechnology Series is Investing in Biotechnology - Financial Perspectives & Evaluation Strategies, published in June 2002. Linking venture capitalists, portfolio managers, biotechnology and pharmaceutical companies, this report provides a unique framework for the valuation of biotechnology companies. It covers the concepts and applications that will help the biotechnology industry get to grips with the finance industry, and vice versa. For more information, call us on +44 (0) 20 8332 8965/6 or email us at scripreports@pjbpubs.com, quoting Ref: BS1165, or visit our website. |
 |